Nxera Pharma: Good results in phase 2 clinical trials of schizophrenia drug candidate NBI-1117568, which is a partnership program with Neurocline

JPX · Aug 28 19:05

The translation is provided by third-party software.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.